Blockade of S1PR1 is commonly employed using the sphingosine analog fingolimod to reduce immune trafficking in multiple sclerosis; fingolimod may also inhibit ceramide synthases, SK1, and SPL and was proposed as a possible therapeutic for glioblastoma (144, 151). Here, S1PR1 is linked to glioblastoma.